Work Here?
Overview
Shasqi develops cancer treatments using click chemistry. Its main product is SQ3370, a Doxorubicin-based therapy designed for patients with advanced solid tumors. The approach uses simple, reliable chemical reactions to create more effective and targeted drug molecules, aiming to improve how doxorubicin fights cancer. The company advances its therapies through research, development, and partnerships with larger pharmaceutical companies (such as Johnson & Johnson) to bring products to market. Its customers are healthcare providers and oncology patients. Overall, Shasqi seeks to bring targeted cancer treatments to patients by collaborating with big pharma to develop and commercialize its drug candidates.
About Shasqi
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series B
Total Funding
$63.5M
Headquarters
San Francisco, California
Founded
2015
People at Shasqi
People at Shasqi who can refer or advise you
Simplify's Take
What believers are saying
- Shasqi secured over $8 million in NIH grants since 2021 to support pipeline-expanding projects.
- The company is advancing a diverse pipeline targeting HER2, TROP2, and NECTIN-4 with effective tumor activation.
- Preclinical data shows sustained tumor regression using antigen-bound activators for targeted drug activation.
What critics are saying
- Phase 2a failure of SQ3370 in solid tissue sarcoma due to lack of durable tumor regression occurs in 6–12 months.
- Moderna’s mRNA-ADC platform displaces SQ3370 with superior tissue penetration and lower cardiac toxicity in 12–18 months.
- FDA rejects SQ3370 for soft-tissue sarcoma due to insufficient antigen-specific activation evidence in 9–15 months.
What makes Shasqi unique
- Shasqi is the first company to use Nobel Prize-winning click chemistry in vivo to activate cancer drugs at the tumor site.
- Phase 1 study of SQ3370 showed no dose-limiting toxicities at over 15x the conventional doxorubicin dose-equivalent.
- In 2023, Shasqi strengthened its partnership with Johnson & Johnson to advance the CAPAC platform.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$63.5M
Above
Industry Average
Funded Over
6 Rounds
Y CombinatorIndustry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
401(k) Company Match
Flexible Work Hours
Remote Work Options
Home Office Stipend
Company Equity
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Alongside the inaugural SAB, Shasqi also announced the expansion of its leadership team with the appointment of Jean-Frédéric Viret, PhD as Chief Financial Officer and Mukul Agarwal as Chief Business Officer.
Shasqi is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Shasqi
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series B
Total Funding
$63.5M
Headquarters
San Francisco, California
Founded
2015
Shasqi is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today